MetaCap

Pacific Biosciences of California (PACB) vs 10x Genomics (TXG)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

10x Genomics (TXG) has outperformed Pacific Biosciences of California (PACB) over the past year, gaining 182.4% versus a loss of 26.6%. Over five years, TXG leads with a -65.2% price change compared with -93.0% for PACB. 10x Genomics is the larger company by market cap ($6.81 billion vs $508.9 million), about 13.4 times the size.

10x Genomics converts more of its revenue into profit, with a net margin of -6.8% versus -341.5%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

PACB-26.58%TXG+182.44%
+457%+191%-74%
Nov 21, 20251 yearNov 20, 2026
PACB-93.84%TXG-65.46%
+5%-48%-101%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

PACB versus TXG key metrics
MetricPACBTXG
Share price$1.63$51.80
Market cap$508.95M$6.81B
1-day change-7.39%-9.72%
YTD return-12.83%+217.60%
1-year return-26.58%+182.44%
5-year return-93.01%-65.20%
Forward P/E—597.67
EPS (TTM)$-0.42$-0.52
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$160.00M$642.82M
Revenue growth (YoY)+3.89%+5.25%
Net income (latest FY)$-546.38M$-43.54M
Gross margin28.61%69.05%
Operating margin-346.15%-9.49%
Net margin-341.47%-6.77%
52-week high$3.44$102.81
52-week low$1.07$15.18
Distance from 52-week high-52.62%-49.62%
Analyst consensusbuybuy
Avg. price target upside+68.10%+31.54%
Average volume13.23M3.36M
Shares outstanding312.24M121.46M
Employees4851,178
SectorIndustrialsIndustrials
IndustryBiotechnology: Laboratory Analytical InstrumentsBiotechnology: Laboratory Analytical Instruments

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • 10x Genomics is about 13.4 times larger than Pacific Biosciences of California by market value ($6.81B vs $508.95M).
  • TXG has outperformed PACB by 209.0 percentage points over the past year.
  • 10x Genomics is more profitable, keeping -6.8 cents of every revenue dollar as net income versus -341.5 cents for Pacific Biosciences of California.

About Pacific Biosciences of California

PACB stock →

Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing solutions to resolve genetically complex problems.

Industrials · Biotechnology: Laboratory Analytical Instruments · 485 employees

About 10x Genomics

TXG stock →

10x Genomics, Inc. develops and sells instruments, consumables, and software for analyzing biological systems in the United States, rest of the Americas, Europe, the Middle East, Africa, China, and the rest of the Asia Pacific.

Industrials · Biotechnology: Laboratory Analytical Instruments · 1,178 employees

PACB vs TXG FAQ

Which is bigger, Pacific Biosciences of California or 10x Genomics?

10x Genomics (TXG) is larger, with a market capitalization of $6.81B compared with $508.95M for Pacific Biosciences of California (PACB).

Which stock has performed better over the past year, PACB or TXG?

TXG returned +182.44% over the past 12 months, compared with -26.58% for PACB (price return, excluding dividends). Past performance does not predict future results.

Are Pacific Biosciences of California and 10x Genomics in the same industry?

Yes. Both are classified in the Biotechnology: Laboratory Analytical Instruments industry within the Industrials sector.

More comparisons